FDA approves Sanofi sugar-lowering drug Soliqua ® 100/33 expansion

recently, the U.SFood andDrug(http://Administration (
FDA(http://) approved the expanded use of Sanofi's sugar-lowering drug Soliqua ® 100/33 (insulin glargine and lisine peptide injections, 100 units/ml and 33 micrograms/ml)Soliqua 100/33 is an injectable drug that is injected once a day and has previously been approved as an additional treatment for diet and exercise for the treatment of long-acting insulin or lisinate for the treatment of adult sequester type 2 diabetes with uncontrolled blood sugarnow, Soliqua 100/33 can also be used to treat adult patients with uncontrolled blood sugar type 2 diabetes with oral anti-sugar drugsSoliqua 100/33 was approved by the FDA in November 2016 and consists of a fixed dose of basic insulin glargine (100U/mL) and a glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lixisenatide ( Lisila peptide, 33mcg/mL) with complementary hypoglycemic effects, the base insulin glargine acts on fasting blood sugar, while lixisenatide acts on post-meal blood sugar, both of which help reduce hbA1c levelsThis approval is based on data from a clinical study of LixiLan-O, which showed that soliqua 100/33 treatment sq100/33 treatment significantly reduced blood sugar levels (-1.6%, -1.3%, -0.9; p 0.0001) compared to insulin glargine and lisesine in patients with type 2 diabetes who received metformin and/or a second oral anti-sugar drugIn addition, there was a significant increase in patients in the Soliqua 100/33 treatment group (74%) who met their target blood sugar levels compared to the insulin glargine treatment group (59%) or the Lissina peptide treatment group (33%)Soliqua 100/33 (25.6%) had similar hypoglycemia events to insulin glargine (23.6%), but lisinapeptide (6.4%) had lower hypoglycemia eventsThe most common adverse reactions in patients in the Soliqua 100/33 treatment group at the beginning of treatment were nausea (9.6%) and vomiting (3.2%)